PAYS Earnings Date: Nov 9, 2026 (Estimated) — Paysign, Inc.
NASDAQ · Technology · Software - Infrastructure
Updated
When is PAYS's next earnings date?
Paysign, Inc. (PAYS) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.09 on revenue of $29.0M.
How did PAYS do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Paysign, Inc. posted EPS of $0.11 versus the $0.06 estimate, a beat of 37.5%. Revenue was $28.3M against a $26.4M estimate. The stock's 1-day post-earnings move was +29.3%.
How much does PAYS stock move after earnings?
PAYS beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 16.0% (up or down) in the day after earnings.
About Paysign, Inc.
Paysign, Inc. provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. The company offers solutions for corporate rewards, prepaid gift cards, general-purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card and software solutions. It also operates a customer service center; and offers a communication suite, including mobile app, two-way SMS, text alerts, and cardholder web portal. The company markets its prepaid card solutions under the Paysign brand. It serves companies and municipalities that require payment solutions for rewards, rebates, payment assistance, and other payments to their customers, employees, agents, and others. Paysign, Inc. was founded in 2001 and is headquartered in Henderson, Nevada.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | 0.06 | 0.11 | +37.50% | $28.3M | ✅ Beat | +29.30% | +33.47% | +35.14% |
| 2026-05-12 | Q1 2026 | 0.10 | 0.09 | -10.00% | $28.0M | ❌ Miss | -12.33% | -10.38% | +0.60% |
| 2026-03-24 | Q4 2025 | 0.03 | 0.02 | -33.33% | $22.8M | ❌ Miss | +36.60% | +56.50% | +61.54% |
| 2025-11-12 | Q3 2025 | 0.04 | 0.04 | +0.00% | $21.6M | ➖ Inline | +0.00% | -5.85% | +0.37% |
| 2025-08-05 | Q2 2025 | 0.04 | 0.02 | -50.00% | $19.1M | ❌ Miss | -26.69% | -23.60% | -26.40% |
| 2025-03-25 | Q4 2024 | 0.03 | 0.02 | -33.33% | $15.6M | ❌ Miss | -8.47% | -14.52% | -2.82% |
| 2024-11-05 | Q3 2024 | 0.01 | 0.03 | +200.00% | $15.3M | ✅ Beat | +6.01% | +0.52% | -12.01% |
| 2024-07-31 | Q2 2024 | 0.02 | 0.01 | -50.00% | $14.3M | ❌ Miss | -8.63% | -16.89% | -11.44% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $28.3M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Pharma Industry | 51.9% | $14.6M | +88.9% | $10.0M | $8.6M | $7.8M | $7.9M |
| Plasma Industry | 46.2% | $13.0M | +21.4% | $21.2M | $9.4M | $10.7M | $12.9M |
| Other Revenue | 2.0% | $562K | -3.1% | $494K | $570K | $581K | $815K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.